- Details
- Description
-
Packaging Size1 vail/Box
-
Strength45mg(0.5ml)
-
CompositonUstekinumab
-
TreatmentInflammation
-
FormInjection
-
Brand赛乐信
-
Quantity Unit45mg(0.5ml)*1vail/Box
-
ManufacturerEastChina Pharm., China
About Ustekinumab
Ustekinumab is a monoclonal antibody medication used for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis,targeting both IL-12 and IL-23.It is administered either by intravenous infusion or subcutaneous injection. The antibody targets a subunit of human interleukin 12 and interleukin 23, which are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. Ustekinumab is a fully human IgG1κ monoclonal antibody that binds to the p40 subunit of interleukin 12 and 23, thereby preventing them from binding to the IL 12Rβ1 receptor expressed on the surface of immune cells. By doing so, ustekinumab prevents the activation of the Th1 and Th17 cytokine pathways, which are central to the pathology of plaque psoriasis, psoriatic arthritis and Crohn's disease.
Plaque Psoriasis
Stelara, Imuldosa, Otulfi, Pyzchiva, Selarsdi, Starjemza, Steqeyma, Wezlana, Yesintek
Indicated for moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy
≤100 kg: 45 mg SC at Weeks 0 and 4, then q12weeks thereafter
>100 kg: 90 mg SC at Weeks 0 and 4, then q12weeks thereafter
Psoriatic Arthritis
Indicated for adults with active psoriatic arthritis alone or in combination with methotrexate
45 mg SC at Weeks 0 and 4, then q12weeks thereafter
For patients who weigh >100 kg with co-existent moderate-to-severe plaque psoriasis, increase dose to 90 mg SC at Weeks 0 and 4, then q12weeks thereafter
Dosing & Uses
Plaque Psoriasis
Indicated for moderate to severe plaque psoriasis in patients who are candidates for phototherapy or systemic therapy
≤100 kg: 45 mg SC at Weeks 0 and 4, then q12weeks thereafter
>100 kg: 90 mg SC at Weeks 0 and 4, then q12weeks thereafter
Psoriatic Arthritis
Indicated for adults with active psoriatic arthritis alone or in combination with methotrexate
45 mg SC at Weeks 0 and 4, then q12weeks thereafter
For patients who weigh >100 kg with co-existent moderate-to-severe plaque psoriasis, increase dose to 90 mg SC at Weeks 0 and 4, then q12weeks thereafter
Crohn Disease
Indicated for adults with moderately to severely active Crohn disease
Initial weight-based IV dose
- Single IV dose infused over 1 hr (also see maintenance dose below)
- ≤55 kg: 260 mg IV
- >55 kg to 85 kg: 390 mg IV
- >85 kg: 520 mg IV
Maintenance SC dose
- Begin 90 mg SC 8 weeks after initial IV infusion, then q8wk thereafter
Ulcerative Colitis
Indicated for adults with moderately to severely active ulcerative colitis
Initial weight-based IV dose
- Single IV dose infused over 1 hr (also see maintenance dose below)
- ≤55 kg: 260 mg IV
- >55 kg to 85 kg: 390 mg IV
- >85 kg: 520 mg IV
Maintenance SC dose
- Begin 90 mg SC 8 weeks after initial IV infusion, then q8wk thereafter
Dosage Modifications
Renal or hepatic impairment: Safety and efficacy not established
